TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02665247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-SIP
Description: In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.

Intervention type: OTHER
Group type: OTHER
Intervention: Dream discussion
Description: Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
Study: NCT01965353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: - Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
Study: NCT04431895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG
Description: tofacitinib 5 mg tablet administered twice a day for 6 months
Study: NCT03934151

Intervention type: PROCEDURE
Intervention: intracorporeal ileocolic anastomosis
Description: laparoscopic bowel transection and ileocolic anastomosis performed inside the abdomen with specimen retrieval in plastic bag

Intervention type: PROCEDURE
Intervention: extracorporeal ileocolic anastomosis
Description: ileocolic anastomosis is carried out by exteriorizing the bowel through a limited laparotomy
Study: NCT04079634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal warming
Description: Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard temperature probe monitoring
Study: NCT02136953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
Study: NCT03477487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Human IL-10 variant transgene in a plasmid DNA vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Human IL-10 variant transgene in a plasmid DNA vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Human IL-10 variant transgene in a plasmid DNA vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Human IL-10 variant transgene in a plasmid DNA vector
Study: NCT02032082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbone monoxide
Study: NCT04548323

Intervention type: BEHAVIORAL
Intervention: Motor imagery
Description: Subjects will perform motor imagery tasks on the motor gestures of running and walking.

Intervention type: BEHAVIORAL
Intervention: Motor imagery
Description: Subjects will perform motor imagery tasks on the motor gestures of running and walking.
Study: NCT04702321

Intervention type: OTHER
Intervention: Procedure: Biospecimen Collection
Description: Collection of saliva, buccal swabs, blood, or other sample adequate for germline DNA extraction

Intervention type: OTHER
Intervention: Procedure: Medical Chart Review
Description: Collection of clinical data
Study: NCT02410460

Intervention type: DRUG
Group type: OTHER
Intervention: clonidine

Intervention type: DRUG
Group type: OTHER
Intervention: clonidine

Intervention type: DRUG
Group type: OTHER
Intervention: glycopyrrolate

Intervention type: DRUG
Group type: OTHER
Intervention: propofol

Intervention type: DRUG
Group type: OTHER
Intervention: ketamine

Intervention type: DRUG
Group type: OTHER
Intervention: marcaine

Intervention type: DRUG
Group type: OTHER
Intervention: marcaine

Intervention type: DRUG
Group type: OTHER
Intervention: scopolamine

Intervention type: DRUG
Group type: OTHER
Intervention: midazolam

Intervention type: DEVICE
Group type: OTHER
Intervention: ondansetron

Intervention type: DRUG
Group type: OTHER
Intervention: metoclopramide

Intervention type: DRUG
Group type: OTHER
Intervention: glycopyrrolate

Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine

Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine

Intervention type: DRUG
Group type: OTHER
Intervention: famotidine

Intervention type: DRUG
Group type: OTHER
Intervention: desflurane

Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane
Study: NCT03165747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: 8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo sachets taken orally daily in a single administration.
Study: NCT04454931

Intervention type: DEVICE
Intervention: Root® with O3® Regional Oximetry
Description: May help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.~It was aimed to determine the appropriate head height that should be given to patients in order to correct the endotracheal suctioning sequence, which is the most important care application of the neurosurgery patients who are followed up in the intensive care unit after surgery, and the possibility of subsequent disruption of cerebral perfusion. Therefore, cerebral oxygenation status, which is the most important parameter that shows the cerebral perfusion status of patients during and after the application, will be followed up by nurses with a non-invasive cerebral oximeter device.
Study: NCT04226417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
Study: NCT05023122

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: vitamin D3 (cholecalciferol) 800 IU QD

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: calcium citrate 600 mg QD

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: calcium citrate 600 mg QD
Study: NCT00221013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: augmented CRRT regimen
Description: We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: augmented CRRT regimen
Description: We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
Study: NCT01143285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and active nutritional support.
Description: The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
Study: NCT05108701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Psychotherapy
Description: Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Psychotherapy
Description: Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
Study: NCT03464435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
Study: NCT03854331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience program
Description: The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
Study: NCT01820663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: A high fat, high protein, low- carbohydrate diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
Study: NCT02001701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal Injection of sulfahexafluoride gas
Description: After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
Study: NCT06167941

Intervention type: BIOLOGICAL
Intervention: Lung cancer types
Description: Cancer tissue matched to normal tissue, all from the same patient
Study: NCT01163552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Description: Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
Study: NCT04668417

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link
Description: Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link
Description: Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
Study: NCT04058509

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy
Description: 3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
Study: NCT03675568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cultured keratinocyte suspension
Description: A new method for treatment of burn wounds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin Graft
Description: A traditional method for treatment of burn wounds
Study: NCT01528410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALFApump removal of ascites
Description: Implanted ALFApump, removing produced ascites according to programmed schedule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large volume paracentesis for removal of ascites
Description: Large volume paracentesis - standard of care, removing ascites according to patient need
Study: NCT02121860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Study: NCT01661738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group ACYW135 Meningococcal Polysaccharide Vaccine
Description: 360 subjects were divided into three groups (120 subjects in each group), children (2\~6 years of age), early youth (7\~15 years of age) and adult (16\~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
Study: NCT04375163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic intense exercise protocol
Description: The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic intense exercise protocol
Description: The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage treatment
Description: Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set.
Study: NCT02717195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 4-6 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 4-6 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 15-20 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 15-20 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 10 mg/day, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 20 mg/day, encapsulated tablets, orally
Study: NCT04640922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gedea Pessary pHyph
Description: Vaginal tablet

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal tablet
Study: NCT01149655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Study: NCT03198845

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video game
Description: 20-min per session for 3 times per week for a 4-week duration

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercise
Description: 20-min per session for 3 times per week for a 4-week duration
Study: NCT03308669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Administered orally
Study: NCT01081626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (follitropin alpha)
Description: A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (follitropin alpha)
Description: A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
Study: NCT02003144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eculizumab
Study: NCT01274351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: administered orally at a dose of 300 mg twice daily for 24 months
Study: NCT00032591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weekly patient self-testing of prothrombin time

Intervention type: OTHER
Group type: OTHER
Intervention: High quality anticoagulation management (HQACM) with conventional monthly testing
Description: HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
Study: NCT01212094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline
Study: NCT00608400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarinol CLA
Description: 0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarinol CLA
Description: 0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Clarinol CLA
Description: 0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
Study: NCT02245815

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: use probiotics boucardii
Description: group A was administered the lactobacillus acidophilus boucardii probiotic (1x10⁹ colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: use probiotics Multi-species
Description: Group B was administered multi-species probiotic (1x10⁹colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.